ReviewMolecular cancer2014
Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.
Review in Molecular cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Review
- Significant Advancements and Evolutions in Chimeric Antigen Receptor Design.International journal of molecular sciences · 2024Review
- CAR-T cell therapy: a game-changer in cancer treatment and beyond.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges.Current pharmaceutical biotechnology · 2024Review
- CAR-T treatment for cancer: prospects and challenges.Frontiers in oncology · 2023Review
- Single-cell RNA-Seq reveals the potential risk of anti-mesothelin CAR T Cell therapy toxicity to different organs in humans.Frontiers in immunology · 2022Article
- Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cells.Molecular therapy. Methods & clinical development · 2021Article
- Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells.Bioengineered · 2021Article
- Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Review
- The 100 Most Influential Studies in Chimeric Antigen Receptor T-Cell: A Bibliometric Analysis.Frontiers in medical technology · 2020Article
- Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture.Frontiers in immunology · 2020Review
- Emerging trends in the immunotherapy of pancreatic cancer.Cancer letters · 2018Review
- Driving better and safer HER2-specific CARs for cancer therapy.Oncotarget · 2017Article
- Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.Molecular therapy oncolytics · 2017Article
- Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.Oncotarget · 2017Review
- Amatuximab and novel agents targeting mesothelin for solid tumors.OncoTargets and therapy · 2017Review
- Novel agents for the treatment of childhood leukemia: an update.OncoTargets and therapy · 2017Review
- Basis for molecular diagnostics and immunotherapy for esophageal cancer.Expert review of anticancer therapy · 2017Review
- New Strategies for the Treatment of Solid Tumors with CAR-T Cells.International journal of biological sciences · 2016Review
- Potential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cells.OncoTargets and therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptors (CARs) are recombinant receptors that combine the specificity of an antigen-specific antibody with the T-cell's activating functions. Initial clinical trials of genetically engineered CAR T cells have significantly raised the profile of T cell therapy, and great efforts have been made to improve this approach. In this review, we provide a structural overview of the development of CAR technology and highlight areas that require further refinement. We also discuss critical issues related to CAR therapy, including the optimization of CAR T cells, the route of administration, CAR toxicity and the blocking of inhibitory molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.